These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8341300)

  • 21. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The subacute levodopa test for evaluating long-duration response in Parkinson's disease.
    Quattrone A; Zappia M; Aguglia U; Branca D; Colao R; Montesanti R; Nicoletti G; Palmieri A; Parlato G; Rizzo M
    Ann Neurol; 1995 Sep; 38(3):389-95. PubMed ID: 7668824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J; Möller B; Witt K; Pinsker MO; Deuschl G; Volkmann J
    Mov Disord; 2009 Jun; 24(8):1206-10. PubMed ID: 19412937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 28. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
    Bara-Jimenez W; Dimitrova T; Sherzai A; Favit A; Mouradian MM; Chase TN
    Mov Disord; 2004 Oct; 19(10):1183-6. PubMed ID: 15390018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.
    Morgante L; Epifanio A; Spina E; Di Rosa AE; Zappia M; Basile G; La Spina P; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S89-90. PubMed ID: 12548358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cisapride on response fluctuations in Parkinson's disease.
    Djaldetti R; Koren M; Ziv I; Achiron A; Melamed E
    Mov Disord; 1995 Jan; 10(1):81-4. PubMed ID: 7885359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics.
    Juncos JL
    Neurol Clin; 1992 May; 10(2):487-509. PubMed ID: 1584186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
    Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
    Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clozapine-responsive tremor in Parkinson's disease.
    Friedman JH; Lannon MC
    Mov Disord; 1990; 5(3):225-9. PubMed ID: 2388638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease.
    Ruggieri S; De Pandis MF; Bonamartini A; Vacca L; Stocchi F
    Clin Neuropharmacol; 1997 Jun; 20(3):204-9. PubMed ID: 9197942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.